Philippe Chollet
Clermont-ferrand, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Journal: Cancer medicine
Published: November 16, 2020
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Journal: International journal of cancer
Published: July 22, 2020
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Journal: Cancer medicine
Published: February 10, 2020
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 06, 2019
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Journal: Oncology
Published: June 11, 2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Journal: Oncology
Published: April 15, 2015
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Journal: International journal of cancer
Published: June 30, 2014
Drimane-Type Sesquiterpene Coumarins from Ferula gummosa Fruits Enhance Doxorubicin Uptake in Doxorubicin-Resistant Human Breast Cancer Cell Line.
Journal: Journal of traditional and complementary medicine
Published: May 27, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 16, 2014
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Journal: Critical reviews in oncology/hematology
Published: March 22, 2014
Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.
Journal: Oncology
Published: January 06, 2014
Last Updated: 09/26/2026